炔雌醇/诺孕酯(Ethinyl Estradiol/Norgestimate) - 药物靶点：ER x PR_在研适应症：避孕_专利_临床

A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a monophasic hormonal contraceptive treatment with norgestimate + ethinylestradiol in Italy. - NA

开始日期2023-03-20

申办/合作机构

Italfarmaco SpA

NCT04828824 / Recruiting临床4期IIT

Reduction of Premature Discontinuation of Contraceptive Implants by Advance Provision of an OCP-based Participant Intervention: Randomized Clinical Trial

To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given standard counseling (comparator).

开始日期2021-06-18

申办/合作机构

University of Colorado Denver

NCT04172987 / Completed临床1期

Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected.
Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.

开始日期2020-02-26

申办/合作机构

Eli Lilly & Co.

100 项与炔雌醇/诺孕酯相关的临床结果

登录后查看更多信息

100 项与炔雌醇/诺孕酯相关的转化医学

登录后查看更多信息

100 项与炔雌醇/诺孕酯相关的专利（医药）

登录后查看更多信息

63

项与炔雌醇/诺孕酯相关的文献（医药）

2021-09-20·Inorganic chemistry2区 · 化学

Antiparallel Coupling between a 4f System and a Photoexcited Cyclic π System in a Dysprosium(III) Monoporphyrinato Complex

2区 · 化学

Article

作者: Ishikawa, Naoto ; Santria, Anas

Magnetic coupling resulted by an orbital angular momentum L of a photoexcited cyclic π-conjugated system and total angular momentum J of a localized 4f electronic system in [Dy(TPP)(cyclen)]Cl (TPP = 5,10,15,20-tetraphenylporphyrinato; cyclen = 1,4,7,10-tetraazacyclododecane) has been identified using magnetic circular dichroism (MCD). The MCD A-term patterns of the compound show a negative increment in the intensity by decreasing temperature and nonproportionality to the magnetic field. This phenomenon is experimentally observed for the first time in porphyrin-based lanthanide complexes and indicates the presence of the J-L interaction, with the preferred orientation being antiparallel. A theoretical model in which J and L are assumed to couple antiferromagnetically yielded a quantitative agreement to the experimental data of varied-temperature and varied-magnetic-field MCD spectral measurements. The ab initio calculations were performed, revealing the relationship between two orbital angular momenta, i.e., L(π) and L(f), which result from the delocalized π system and the localized 4f system, respectively.

2018-02-01·Current treatment options in cardiovascular medicine

Transradial PCI and Same Day Discharge

Review

作者: Elfandi, Ali ; Safirstein, Jordan G

PURPOSE OF REVIEW:

The evolution of cardiac catheterization has led to the development of well-refined, more effective, and safer devices that allow cardiovascular interventionalists to deliver high-quality percutaneous interventions (PCI). Transradial PCI (TRI) has gained more popularity in the USA over the past 10 years, and as experience and volume of TRI grow, studies adopting same day radial PCI protocols have emerged and are showing promising results. We sought to review the current literature on TRI and same day discharge (SDD).

RECENT FINDINGS:

This literature review was performed to evaluate the studies that were published over the last 17 years regarding TRI and SDD. A literature search using PubMed, Cochran database, Google Scholar, and Embase was performed for studies evaluating TRI and SDD from January 1, 2000, to August 1, 2017. Observational studies, randomized clinical trials, meta-analyses, and consensus statements were included in our review. We used the following terms in our search: "same day," "same day discharge," "outpatient," and "ambulatory radial PCI." Articles with data pertinent to the subject matter were included. We did not limit our searches to specific journals. The available literature supports SDD for selected radial PCI patients. The advancement in PCI devices and pharmacology has enhanced the safety of post-PCI disposition leading to the evolution from traditional overnight stays to the development of same day discharge programs. We conclude that outpatient TRI for appropriately selected patients will be the standard of care in the future. This will lead to increased patient satisfaction, improved hospital throughput, and reduced hospital costs, without increased procedural complications.

2017-11-01·Clinical pharmacokinetics2区 · 医学

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide

2区 · 医学

Article

作者: Geiser, Jeanne ; Loghin, Corina ; Cui, Xuewei ; de la Peña, Amparo

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes mellitus are known to delay gastric emptying (GE). The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated.

METHODS:

In four separate clinical pharmacology studies, digoxin, warfarin, atorvastatin and Ortho-Cyclen^® were orally administered to healthy subjects with and without a subcutaneous dose of dulaglutide 1.5 mg. The effect of dulaglutide coadministration was assessed based on the PK parameters of key analytes. For warfarin PD, the effect of dulaglutide on the international normalized ratio (INR) was evaluated.

RESULTS:

Areas under the concentration-time curves (AUCs) with and without dulaglutide were similar for all analytes except atorvastatin, where it was reduced by 21%. Maximum concentrations (C _max) were generally lower following coadministration with dulaglutide, with statistically significant reductions (90% confidence intervals of geometric least squares means ratios outside 0.80-1.25) for all analytes except R-warfarin. For all analytes, there was a general trend for the time to C _max (t _max) to increase following coadministration with dulaglutide. For warfarin, dulaglutide coadministration had no statistically significant effect on the maximum INR (INR_max); however, a 2% increase in area under the INR curve (AUC_INR) was observed.

CONCLUSIONS:

Dulaglutide did not affect the absorption of the tested medications to a clinically relevant degree. Based on the PK and PD evaluations, no dose adjustments for digoxin, warfarin, atorvastatin and Ortho-Cyclen^® are recommended when coadministered with dulaglutide.

CLINICAL TRIAL REGISTRATION NUMBERS:

NCT01458210, NCT01436201, NCT01432938, and NCT01250834.

1

项与炔雌醇/诺孕酯相关的新闻（医药）

2021-03-04

·BioSpace

Mayne Pharma launches another generic oral contraceptive

ADELAIDE, Australia, March 4, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of a generic version of ORTHO-CEPT® (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US. This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN® 24 FE, ORTHO CYCLEN® and ORTHO TRI-CYCLEN®. According to IQVIA, the annual US market sales for the four products were approximately US$315 million in the twelve months ending January 2021[1]. Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives. Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options. The four new products launched this year were sourced from the strategic partnership with Novast Laboratories." "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS™ (E4/DRSP) and a generic version of NUVARING®. NEXTSTELLIS which has a FDA target action date in April contains a new estrogen called estetrol or E4 in combination with a progestin, drospirenone. If approved, E4 will be the first new estrogen introduced in the US for contraceptive use in approximately 50 years." About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, offering patients better and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world. Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds. LOESTRIN® 24 FE, NEXTSTELLIS™, NUVARING®, ORTHO-CEPT®, ORTHO CYCLEN® and ORTHO TRI-CYCLEN® are registered trademarks of third parties. [1] IQVIA, MAT Sales and NSP Units for brand and generic equivalents, January 2021 Company Codes: Australia:MYX, OTC-PINK:MYPHY

合作

100 项与炔雌醇/诺孕酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G03AA11 G03AB09	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
避孕	美国	Janssen Pharmaceuticals, Inc.	1989-12-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
出血	临床2期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2003-11-01
子宫不规则出血	临床2期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2003-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAN2019	临床1期	-	22	Ubrogepant 50 mg	製壓鬱蓋獵醖壓選製齋(選簾蓋膚顧醖衊膚鬱鹽) = Most (18/21) drug-related adverse events were related to ubrogepant and were mild 餘廠壓壓窪選選鑰選憲 (鏇鹹觸鏇艱鹽觸齋簾膚 ) 更多	积极	2019-04-09
				Ortho-Cyclen (ethinyl estradiol/norgestimate)
NCT01475513 (CTgov)	临床4期	心血管疾病 \| 胰岛素抵抗	47	Ortho Cyclen® (African-American Women)	範範夢獵壓膚築顧製齋(鏇膚壓鏇築鏇繭艱顧淵) = 艱餘鹽顧範築齋觸餘鹽鹹遞範鹹廠選鹽襯簾廠 (醖選繭鹹繭範鹽壓糧鑰, 獵選鏇糧蓋網鏇襯衊鹽 ~ 繭鬱鑰製齋構齋鏇繭廠) 更多	-	2018-07-10
				Ortho Cyclen® (Caucasian Women)	範範夢獵壓膚築顧製齋(鏇膚壓鏇築鏇繭艱顧淵) = 築窪繭鹽淵觸壓壓製壓鹹遞範鹹廠選鹽襯簾廠 (醖選繭鹹繭範鹽壓糧鑰, 遞餘壓醖醖選獵淵鑰網 ~ 醖網獵窪鏇壓醖壓選網) 更多
NCT00775190 (CTgov)	N/A	避孕	12	ortho tricyclen (Ortho Tricyclen™)	顧餘構鬱鹽鹹憲鹽鬱願(糧鏇醖鑰壓壓構齋繭製) = 鏇衊獵顧鑰襯襯顧鏇醖艱襯網膚窪廠繭醖網網 (積範蓋願鬱網獵糧醖艱, 鹹蓋鑰顧餘構艱憲蓋顧 ~ 鏇鹽糧繭顧衊觸膚鑰選) 更多	-	2017-04-17
				Trinessa (Trinessa™)	顧餘構鬱鹽鹹憲鹽鬱願(糧鏇醖鑰壓壓構齋繭製) = 繭衊觸遞網餘遞網鏇鑰艱襯網膚窪廠繭醖網網 (積範蓋願鬱網獵糧醖艱, 獵獵鑰憲鬱獵製艱製廠 ~ 膚憲鑰願簾鏇壓鏇衊鹹) 更多
NCT01466673 (CTgov)	临床4期	寻常痤疮	201	Ethinyl estradiol/Norgestimate (EE/NGM) (Ethinyl Estradiol/Norgestimate (EE/NGM))	製築蓋糧鏇糧齋遞衊網(鑰蓋糧衊遞鹽範夢顧願) = 襯築蓋衊願築鏇鹽製繭醖願範廠構憲網鹹鏇艱 (餘網獵觸遞衊艱繭製膚, 顧糧鏇餘醖鹽衊憲積範 ~ 網製醖齋餘鹹簾鬱餘夢) 更多	-	2013-06-19
				Ethinyl estradiol/Desogestrel (EE/DSG) (Ethinyl Estradiol/Desogestrel (EE/DSG))	製築蓋糧鏇糧齋遞衊網(鑰蓋糧衊遞鹽範夢顧願) = 衊鏇憲顧選鏇鏇艱餘鏇醖願範廠構憲網鹹鏇艱 (餘網獵觸遞衊艱繭製膚, 襯願積繭鏇艱夢願廠築 ~ 選鑰壓廠選範製製齋夢) 更多
NCT00635570 (ACCEPT, CTgov)	临床4期	避孕	273	NuvaRing (Contraceptive Vaginal Ring)	築鹹壓壓艱夢壓夢齋鑰(鑰繭壓襯鏇壓觸淵選構) = 範壓衊願鹽鑰觸壓鬱繭糧鏇憲餘獵鬱膚糧鬱鏇 (夢廠艱簾襯淵醖鏇糧獵, 繭艱顧淵鬱網憲蓋壓繭 ~ 願積鏇糧築糧願獵廠艱) 更多	-	2012-11-07
				Ortho Tri-cyclen Lo (Oral Contraceptive Pill)	築鹹壓壓艱夢壓夢齋鑰(鑰繭壓襯鏇壓觸淵選構) = 繭夢鑰鹽鹽製簾糧網淵糧鏇憲餘獵鬱膚糧鬱鏇 (夢廠艱簾襯淵醖鏇糧獵, 獵襯齋蓋願遞膚範簾糧 ~ 積糧簾窪積齋窪積願簾) 更多
NCT00205504 (Pubmed \| Fertil Steril)	临床4期	胰岛素抵抗	46	combined hormonal oral contraceptive (Lean women)	淵選製積糧繭壓簾顧艱(艱鑰獵鏇範遞襯構選觸) = 構艱夢鹹積鬱夢構蓋淵製網製簾蓋襯築鹹鹽餘 (淵夢淵築獵遞衊壓範糧 )	-	2011-08-01
				combined hormonal oral contraceptive (Obese women)	淵選製積糧繭壓簾顧艱(艱鑰獵鏇範遞襯構選觸) = 窪夢觸觸壓範鏇獵蓋憲製網製簾蓋襯築鹹鹽餘 (淵夢淵築獵遞衊壓範糧 )